Compare KRO & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRO | CMPS |
|---|---|---|
| Founded | 1916 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 730.6M | 724.5M |
| IPO Year | 2004 | 2020 |
| Metric | KRO | CMPS |
|---|---|---|
| Price | $6.58 | $5.59 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $6.00 | ★ $26.57 |
| AVG Volume (30 Days) | 348.2K | ★ 1.9M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,859,400,000.00 | N/A |
| Revenue This Year | $6.75 | N/A |
| Revenue Next Year | $8.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.08 | $2.25 |
| 52 Week High | $7.90 | $8.90 |
| Indicator | KRO | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 64.18 | 42.93 |
| Support Level | $4.29 | $4.90 |
| Resistance Level | $6.73 | $7.02 |
| Average True Range (ATR) | 0.29 | 0.29 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 90.36 | 70.01 |
Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in various products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The maximum of revenue comes from the United States.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.